Epoprostenol dosing by concomitant therapies in the PROSPECT registry
M. Chakinala, R. Frantz, R. Schilz, W. Benton, D. Miller, B. Hartline, C. L. Vampola, D. Rosenberg, H. Farber (St. Louis, Rochester, Cleveland, South San Francisco, San Francisco, Boston, United States Of America; Allschwil, Switzerland)
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Session: Pulmonary hypertension: clinical management
Session type: Thematic Poster Session
Number: 2373
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Chakinala, R. Frantz, R. Schilz, W. Benton, D. Miller, B. Hartline, C. L. Vampola, D. Rosenberg, H. Farber (St. Louis, Rochester, Cleveland, South San Francisco, San Francisco, Boston, United States Of America; Allschwil, Switzerland). Epoprostenol dosing by concomitant therapies in the PROSPECT registry. Eur Respir J 2014; 44: Suppl. 58, 2373
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: